Drug Shortage Report for CLINIMIX

Last updated on 2021-11-26 History
Report ID 145268
Drug Identification Number 02013940
Brand name CLINIMIX
Common or Proper name CLINIMIX TR5%/D20% 5% Amino Acids (Blend B) without Electrolytes in 20% Dextrose Injection
Company Name BAXTER CORPORATION
Market Status MARKETED
Active Ingredient(s) HISTIDINE L-VALINE L-ISOLEUCINE L-ARGININE GLYCINE L-ALANINE METHIONINE L-LYSINE HYDROCHLORIDE L-PHENYLALANINE HYDROCHLORIDE L-LEUCINE HYDROCHLORIDE DEXTROSE L-TYROSINE L-PROLINE TRYPTOPHAN L-THREONINE
Strength(s) 220MG 230MG 240MG 520MG 1.04G 1.04G 290MG 290MG 310MG 310MG 20G 20MG 210MG 90MG 210MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 1000 mL (JB6762P)
ATC code B05BA
ATC description I.V. SOLUTIONS
Reason for shortage Demand increase for the drug.
Anticipated start date 2021-09-07
Actual start date 2021-09-07
Estimated end date 2021-11-25
Actual end date 2021-11-25
Shortage status Resolved
Updated date 2021-11-26
Company comments Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order.
Health Canada comments
Contact Address 7125 MISSISSAUGA ROAD
MISSISSAUGA, ONTARIO
CANADA L5N 0C2
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v10 2021-11-26 English Compare
v9 2021-11-25 French Compare
v8 2021-11-25 English Compare
v7 2021-10-13 French Compare
v6 2021-10-13 English Compare
v5 2021-10-13 French Compare
v4 2021-10-13 English Compare
v3 2021-09-08 English Compare
v2 2021-09-07 French Compare
v1 2021-09-07 English Compare